West Pharmaceutical Services, Inc. - 2007 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: West Pharmaceutical Services, Inc.
Reporting Period: Fiscal year ended December 31, 2007
Business Overview: West is a global manufacturer of components and systems for injectable drug delivery and plastic packaging for healthcare and consumer markets. The company operates through two primary segments: Pharmaceutical Systems (stoppers, seals, syringe components) and Tech Group (custom injection molding and assembly).
Key Milestone: 2007 marked the first year in company history with consolidated net sales exceeding $1 billion.
Key Financial Metrics (2007)
| Metric | 2007 Value | 2006 Value |
|---|---|---|
| Net Sales | $1,020.1 million | $913.3 million |
| Gross Profit | $291.8 million | $264.8 million |
| Gross Margin | 28.6% | 29.0% |
| Operating Profit | $94.9 million | $101.0 million |
| Net Income | $70.7 million | $67.1 million |
| Diluted EPS (Continuing Ops) | $2.06 | $1.83 |
| Operating Cash Flow | $129.2 million | $139.4 million |
| Total Debt | $395.1 million | $236.3 million |
| Cash & Equivalents | $108.4 million | $47.1 million |
| Working Capital | $229.4 million | $124.8 million |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated net sales increased 11.7% ($106.8 million) driven by the Pharmaceutical Systems segment (+15.2%) and favorable foreign currency translation ($41.4 million). The Tech Group segment saw modest growth of 3.6%.
- Operating Profit Decline: Despite revenue growth, operating profit decreased 6.0% to $94.9 million. This was primarily due to $28.3 million in restructuring, impairment, and other charges (compared to $4.9 million in 2006).
- Debt Structure: Total debt increased significantly due to the issuance of $161.5 million in convertible junior subordinated debentures in March 2007. Proceeds were used to reduce borrowings on the revolving credit facility and fund general corporate purposes.
- Segment Performance:
- Pharmaceutical Systems: Operating profit increased $12.2 million, benefiting from sales growth and favorable product mix.
- Tech Group: Operating profit decreased $6.5 million due to costs associated with relocating a Michigan facility and lower tooling project activity.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Pharmaceutical Systems: Management expects approximately 7% sales growth in 2008, driven by customer conversions to enhanced coated components and demand for pre-fillable syringe components.
- Tech Group: Sales are projected to decline approximately 7% in 2008 due to the loss of the Exubera device revenue and lower tooling activity. However, management expects a leaner cost structure from restructuring to offset these declines.
- Capital Spending: 2008 capital spending is budgeted at approximately $140 million to fund capacity expansions in Europe, Asia, and the U.S.
Unusual Items & Contingencies:
- Exubera Impairment: Recorded a $12.9 million impairment charge on the Nektar contract intangible asset after Pfizer discontinued marketing the Exubera device. No revenue from this device is expected in 2008.
- Restructuring: Approved a $12.0 million restructuring plan for the Tech Group segment to align capacity with business outlook. $3.4 million was incurred in 2007, with $8.6 million expected in 2008.
- Brazilian Tax Issues: Increased accruals for Brazilian tax contingencies by $10.1 million following a review of pending court cases.
Risk Factors:
- Dependence on injectable drug delivery systems; shifts to alternative delivery methods could reduce demand.
- Exposure to raw material price volatility (elastomers, aluminum, plastic) and energy costs.
- Foreign currency fluctuations impacting 51% of sales generated outside the U.S.
- Regulatory compliance risks with the FDA and international agencies.
Investor Verification Checklist
- Exubera Impact: Verify the extent of revenue loss from the Exubera device in 2008 and the effectiveness of the Tech Group restructuring in offsetting this loss.
- Brazilian Tax Resolution: Monitor the status of Brazilian tax litigation and potential additional provisions beyond the $10.1 million accrued.
- Convertible Debt: Assess the dilution risk associated with the $161.5 million convertible debentures (conversion price ~$56.07) if stock prices rise significantly.
- Capacity Expansion: Track the completion and utilization rates of new facilities in Germany, Serbia, Singapore, and the planned China plant to ensure they meet demand forecasts.
- Raw Material Costs: Monitor commodity prices for synthetic elastomers and plastics to evaluate margin pressure in 2008.